R., Plukker, J
Back Edwards, K, Li, X, Linvay, I (1 April 2023) 'Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study', The Journal of Clinical Endocrinology & Metabolism , 108/ 4, 92030
232,233 GLP-1 inhibits the release of glucagon from -cells through multiple mechanisms
[DOI] [PMC free article] [PubMed] [Google Scholar] 22.Subar A.F., Kirkpatrick S.I., Mittl B., et al
Choosing between semaglutide and tirzepatide with Hashimoto's Both semaglutide and tirzepatide are options for Hashimoto's patients, but they work differently and have distinct considerations worth understanding
In the SURMOUNT 1 trial, tirzepatide 15 mg/wk with general nutritional instructions produced a 20.9 % reduction in body weight from baseline (versus 3.1 % with general nutrition instructions alone) [15], whereas in the SURMOUNT 3 trial, tirzepatide 10 or 15 mg/wk started after 12 weeks of intensive lifestyle intervention produced a 25 % reduction from baseline (versus 4.8 % with intensive lifestyle intervention alone) [170]
